# A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)

> **NCT01573000** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 78 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin

## Interventions

- **BIOLOGICAL:** Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)

## Key facts

- **NCT ID:** NCT01573000
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-09
- **Primary completion:** 2001-04
- **Final completion:** 2010-04
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2017-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01573000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01573000, "A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01573000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*